Related Experiment Video
Updated: Jun 20, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
Critical roles for the TSC-mTOR pathway in β-cell function
Hiroyuki Mori1, Ken Inoki, Darren Opland
1Dept. of Pharmacology and Moores Cancer Center, Univ. of California San Diego, La Jolla, CA 92093-081, USA. kuguan@ucsd.edu
Abstract:
TSC1 is a tumor suppressor that associates with TSC2 to inactivate Rheb, thereby inhibiting signaling by the mammalian target of rapamycin (mTOR) complex 1 (mTORC1). mTORC1 stimulates cell growth by promoting anabolic cellular processes, such as translation, in response to growth factors and nutrient signals. To test roles for TSC1 and mTORC1 in β-cell function, we utilized Rip2/Cre to generate mice lacking Tsc1 in pancreatic β-cells (Rip-Tsc1cKO mice). Although obesity developed due to hypothalamic Tsc1 excision in older Rip-Tsc1cKO animals, young animals displayed a prominent gain-of-function β-cell phenotype prior to the onset of obesity. The young Rip-Tsc1cKO animals displayed improved glycemic control due to mTOR-mediated enhancement of β-cell size, mass, and insulin production but not determinants of β-cell number (proliferation and apoptosis), consistent with an important anabolic role for mTOR in β-cell function. Furthermore, mTOR mediated these effects in the face of impaired Akt signaling in β-cells. Thus, mTOR promulgates a dominant signal to promote β-cell/islet size and insulin production, and this pathway is crucial for β-cell function and glycemic control.
Insights
Loss of TSC1 in pancreatic beta cells enhances mTORC1 signaling, leading to larger cells and improved insulin production. This promotes better glycemic control, highlighting mTOR
Area of Science:
- Cell Biology
- Metabolism
- Endocrinology
Background:
- TSC1 (Tuberous Sclerosis Complex 1) acts as a tumor suppressor by inhibiting mTORC1 signaling.
- mTORC1 (mammalian target of rapamycin complex 1) is a key regulator of cell growth and anabolic processes.
- Dysregulation of TSC1 and mTORC1 pathways can impact cellular function and organismal metabolism.
Purpose of the Study:
- To investigate the role of TSC1 and mTORC1 in pancreatic beta-cell function.
- To determine the impact of TSC1 loss on beta-cell size, mass, and insulin production.
- To elucidate the downstream signaling pathways affected by TSC1 loss in beta-cells.
Main Methods:
- Generation of mice with Tsc1 specifically deleted in pancreatic beta-cells (Rip-Tsc1cKO mice) using Rip2/Cre.
- Analysis of young and older Rip-Tsc1cKO mice for metabolic and beta-cell phenotypes.
- Assessment of beta-cell proliferation, apoptosis, size, mass, and insulin production.
- Evaluation of Akt signaling pathway activation in beta-cells.
Main Results:
- Young Rip-Tsc1cKO mice exhibited enhanced beta-cell function, including increased beta-cell size, mass, and insulin production, leading to improved glycemic control.
- These effects were mediated by mTORC1 signaling, independent of changes in beta-cell proliferation or apoptosis.
- Impaired Akt signaling was observed in the beta-cells of Rip-Tsc1cKO mice, yet mTORC1 signaling remained dominant.
- Older Rip-Tsc1cKO animals developed obesity due to hypothalamic Tsc1 excision.
Conclusions:
- mTORC1 signaling is a critical anabolic driver of pancreatic beta-cell size and insulin production.
- The TSC1-TSC2-Rheb-mTORC1 pathway plays a crucial role in maintaining beta-cell function and glycemic control.
- Targeting mTORC1 signaling in beta-cells may offer therapeutic potential for metabolic disorders.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
TGF - β Signaling Pathway
Insulin: The Receptor and Signaling Pathways
cAMP-dependent Protein Kinase Pathways

